Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2004;94:1606-1614
Published online before print May 13, 2004, doi: 10.1161/01.RES.0000132279.99249.f4
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
94/12/1606    most recent
01.RES.0000132279.99249.f4v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakajima, H.
Right arrow Articles by Field, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakajima, H.
Right arrow Articles by Field, L. J.
Related Collections
Right arrow Other myocardial biology
Right arrow Cell biology/structural biology
Right arrow Genetically altered mice
(Circulation Research. 2004;94:1606.)
© 2004 American Heart Association, Inc.


Integrative Physiology

Expression of Mutant p193 and p53 Permits Cardiomyocyte Cell Cycle Reentry After Myocardial Infarction in Transgenic Mice

Hidehiro Nakajima, Hisako O. Nakajima, Shih-Chong Tsai, Loren J. Field

From the Wells Center for Pediatric Research and Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Ind. Present address for S.-C.T. is the Development Center for Biotechnology, Taipei, Taiwan.

Correspondence to Loren J. Field, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, 1044 West Walnut St, R4 Building, Rm W376, Indianapolis, IN 46202-5225. E-mail ljfield{at}iupui.edu

Previous studies have demonstrated that expression of p193 and p53 mutants with dominant-interfering activities renders embryonic stem cell–derived cardiomyocytes responsive to the growth promoting activities of the E1A viral oncoproteins. In this study, the effects of p53 and p193 antagonization on cardiomyocyte cell cycle activity in normal and infarcted hearts were examined. Transgenic mice expressing the p193 and/or the p53 dominant-interfering mutants in the heart were generated. Transgene expression had no effect on cardiomyocyte cell cycle activity in uninjured adult hearts. In contrast expression of either transgene resulted in a marked induction of cardiomyocyte cell cycle activity at the infarct border zone at 4 weeks after permanent coronary artery occlusion. Expression of the p193 dominant-interfering mutant was also associated with an induction of cardiomyocyte DNA synthesis in the interventricular septa of infarcted hearts. A concomitant and marked reduction in hypertrophic cardiomyocyte growth was observed in the septa of hearts expressing the p193 dominant-interfering transgene, suggesting that cell cycle activation might partially counteract the adverse ventricular remodeling that occurs after infarction. Collectively these data suggest that antagonization of p193 and p53 activity relaxes the otherwise stringent regulation of cardiomyocyte cell cycle reentry in the injured adult heart.


Key Words: cardiomyocyte proliferation • apoptosis • DNA synthesis • heart regeneration




This article has been cited by other articles:


Home page
HeartHome page
R J Hassink, H Nakajima, H O Nakajima, P A Doevendans, and L J Field
Expression of a transgene encoding mutant p193/CUL7 preserves cardiac function and limits infarct expansion after myocardial infarction
Heart, July 15, 2009; 95(14): 1159 - 1164.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. Zhu, M. H. Soonpaa, H. Chen, W. Shen, R. M. Payne, E. A. Liechty, R. L. Caldwell, W. Shou, and L. J. Field
Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway
Circulation, January 6, 2009; 119(1): 99 - 106.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. Lorts, J. A. Schwanekamp, J. W. Elrod, M. A. Sargent, and J. D. Molkentin
Genetic Manipulation of Periostin Expression in the Heart Does Not Affect Myocyte Content, Cell Cycle Activity, or Cardiac Repair
Circ. Res., January 2, 2009; 104(1): e1 - e7.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Tamamori-Adachi, H. Takagi, K. Hashimoto, K. Goto, T. Hidaka, U. Koshimizu, K. Yamada, I. Goto, Y. Maejima, M. Isobe, et al.
Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and Skp2 ubiquitin ligase
Cardiovasc Res, November 1, 2008; 80(2): 181 - 190.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. Ebelt, Y. Zhang, A. Kampke, J. Xu, A. Schlitt, M. Buerke, U. Muller-Werdan, K. Werdan, and T. Braun
E2F2 expression induces proliferation of terminally differentiated cardiomyocytes in vivo
Cardiovasc Res, November 1, 2008; 80(2): 219 - 226.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. R. Crisostomo, A. M. Abarbanell, M. Wang, T. Lahm, Y. Wang, and D. R. Meldrum
Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions
Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1726 - H1735.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. J. Hassink, K. B. Pasumarthi, H. Nakajima, M. Rubart, M. H. Soonpaa, A. B. de la Riviere, P. A. Doevendans, and L. J. Field
Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction
Cardiovasc Res, April 1, 2008; 78(1): 18 - 25.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Li, N. Naqvi, E. Yahiro, K. Liu, P. C. Powell, W. E. Bradley, D. I.K. Martin, R. M. Graham, L. J. Dell'Italia, and A. Husain
c-kit Is Required for Cardiomyocyte Terminal Differentiation
Circ. Res., March 28, 2008; 102(6): 677 - 685.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. W. van Laake, S. van den Driesche, S. Post, A. Feijen, M. A. Jansen, M. H. Driessens, J. J. Mager, R. J. Snijder, C. J. J. Westermann, P. A. Doevendans, et al.
Endoglin Has a Crucial Role in Blood Cell-Mediated Vascular Repair
Circulation, November 21, 2006; 114(21): 2288 - 2297.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. Matsusaka, T. Ide, S. Matsushima, M. Ikeuchi, T. Kubota, K. Sunagawa, S. Kinugawa, and H. Tsutsui
Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice
Cardiovasc Res, June 1, 2006; 70(3): 457 - 465.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Nakajima, H. O. Nakajima, K. Dembowsky, K. B.S. Pasumarthi, and L. J. Field
Cardiomyocyte Cell Cycle Activation Ameliorates Fibrosis in the Atrium
Circ. Res., January 6, 2006; 98(1): 141 - 148.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. M. Regula and L. A. Kirshenbaum
Breaking Down Cell-Cycle Barriers in the Adult Heart
Circ. Res., June 25, 2004; 94(12): 1524 - 1526.
[Full Text] [PDF]